Effect of N-Acetylcysteine on Dyslipidemia and Carbohydrate Metabolism in STZ-Induced Diabetic Rats

Kaga, Anderson Kiyoshi; Barbanera, Pedro Octavio; Carmo, Nágilla Orleanne Lima do; Rosa, Lucas Rodolfo de Oliveira; Fernandes, Ana Angélica Henrique

doi:10.1155/2018/6428630

Cited by 14 publications

(10 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The co-administration of NAC revealed partial recovery of lipid pro le as evidenced by normalization of total cholesterol, triglycerides, HDL-cholesterol and atherogenic index and decrement of LDL-cholesterol con rming the improvement of dyslipidemia, which is supported by previous studies [21,50,51]. The lipid-lowering action of NAC in our MS animal model of hyperlipidemia can be partially ascribed to the suppression of mRNA expression of lipogenic related enzymes [52].…”

Section: Discussionsupporting

confidence: 84%

N-acetyl cysteine can blunt metabolic and cardiovascular effects via down-regulation of cardiotrophin-1 in rat model of fructose-induced metabolic syndrome

Abdelhaffez

El-Aziz

Tohamy

et al. 2021

Archives of Physiology and Biochemistry

View full text Add to dashboard Cite

BackgroundChronic fructose consumption is associated with development of obesity, insulin resistance (IR) and metabolic syndrome (MS). Cardiovascular diseases are linked to metabolic deregulation observed in MS. N-acetylcysteine (NAC) is a sulfur containing compound of Allium plants (such as garlic and onion) that increases intracellular reduced glutathione concentrations, which is an endogenous antioxidant. MethodsThis study investigated the ability of N-acetyl cysteine (NAC) to alleviate the metabolic disorders in fructose-induced MS in male Wistar rats and to examine its protective effect on aortic and cardiac tissues via its in uence on cardiotrophin-1 (CT-1) expression. NAC (20 mg/kg b.w./day) was administered to fructose (20% w/v) induced MS animals for twelve weeks. ResultsChronic fructose consumption increased body weight gain, relative heart weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), IR and associated with metabolic alterations. Histological and immunohistochemical examination revealed aortic stiffness and myocardial degeneration and brosis together with increased CT-1 expression. Treatment with NAC improved IR, SBP, DBP and mitigated atherogenic dyslipidaemia and oxidative stress (OS). Additionally, NAC down-regulated CT-1 expression in the heart and aorta. Furthermore, CT-1 expression in the heart and aorta was positively correlated with basal glycemia, nal SBP and DBP, total cholesterol, triglycerides, low density lipoproteins and negatively correlated with high density lipoproteins levels. ConclusionThe ndings reported here demonstrated, for the rst time, the protective effect of NAC against aortic and myocardial degeneration and brosis through down-regulation of CT-1 in fructose induced MS animal model. Also, our results revealed the infallible role of NAC to blunt the cardiometabolic deregulation observed in MS.

show abstract

Section: Discussionsupporting

confidence: 84%

N-acetyl cysteine can blunt metabolic and cardiovascular effects via down-regulation of cardiotrophin-1 in rat model of fructose-induced metabolic syndrome

Abdelhaffez

El-Aziz

Tohamy

et al. 2021

Archives of Physiology and Biochemistry

View full text Add to dashboard Cite

show abstract

“…Diabetic hyperlipidemia can be regarded for promoting cardiovascular diseases and the management of diabetic dyslepidemia is a key factor in treating diabetes (Kaga et al, 2018). The significant elevation of Triglycerides (TGs), LDL-C and total cholesterol in diabetic rats (group II) in the present study was similar to what was reported previously (Ahmadvand et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Zingerone (4-(4-hydroxy-3-methylphenyl) butan-2-one) protects against alloxan-induced diabetes via alleviation of oxidative stress and inflammation: Probable role of NF-kB activation

Ahmad

Rehman

Amin

et al. 2018

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Diabetes is considered as the most common metabolic disease affecting millions of people all around the world. Use of natural herbal medicines can be effective in treating diabetes. Zingerone (4-(4-hydroxy-3-methylphenyl) butan-2-one) a polyphenolic alkanone extracted from ginger has a broad spectrum of pharmacological properties and thus can be used as a promising candidate against various ailments. In the current study we aimed at demonstrating the protective effect of zingerone against diabetes mellitus and elucidating its possible mechanism. Five groups of animals (I-V) were made with ten animals each. Group I (control) was given normal saline orally. Group II (diabetic positive control) was given alloxan at the dose rate of 100 mg/kg bwt once. Group III and IV was given alloxan once at the dose rate of 100 mg/kg bwt. and received oral treatment of zingerone at a dose rate of 50 and 100 mg/kg bwt respectively daily for 21 days. Group V was given alloxan at the dose of 100 mg/kg bwt. and was treated with standard drug glibenclamide at the dose rate of 4.5 mg/kg bwt. daily for 21 days. According to our findings we confirmed that zingerone restrained the alloxan induced oxidative stress by increasing the activity of reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX) and reducing the peroxidative damage. We also confirmed that zingerone suppressed the level of redox sensitive transcription factor NFκB and downregulated other downstream inflammatory cytokines like interleukins (IL1-β IL-2, IL-6) and tumor necrosis factor alpha (TNF-α). Moreover, the experimental findings suggested that zingerone improved the insulin levels. Taken together our results indicated that zingerone effectively ameliorated the diabetes induced complications which provide a strong theoretical basis for zingerone to be used clinically for treatment of diabetes.

show abstract

“…Animal studies show that NAC may inhibit hepatic steatosis and development of glucose intolerance and improve lipid profiles [ 65 , 66 ]. In type 2 diabetic humans, there does not appear to be any benefit in improving glucose tolerance or ß -cell function with the addition of NAC in short-term trials (2 weeks) [ 67 ].…”

Section: Metabolic Syndrome Including Nonalcoholic Fatty Liver Disease Diabetes and Polycystic Ovarymentioning

confidence: 99%

N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks)

Schwalfenberg

2021

Journal of Nutrition and Metabolism

View full text Add to dashboard Cite

Objective. To review the clinical usefulness of N-acetylcysteine (NAC) as treatment or adjunctive therapy in a number of medical conditions. Use in Tylenol overdose, cystic fibrosis, and chronic obstructive lung disease has been well documented, but there is emerging evidence many other conditions would benefit from this safe, simple, and inexpensive intervention. Quality of Evidence. PubMed, several books, and conference proceedings were searched for articles on NAC and health conditions listed above reviewing supportive evidence. This study uses a traditional integrated review format, and clinically relevant information is assessed using the American Family Physician Evidence-Based Medicine Toolkit. A table summarizing the potential mechanisms of action for N-acetylcysteine in these conditions is presented. Main Message. N-acetylcysteine may be useful as an adjuvant in treating various medical conditions, especially chronic diseases. These conditions include polycystic ovary disease, male infertility, sleep apnea, acquired immune deficiency syndrome, influenza, parkinsonism, multiple sclerosis, peripheral neuropathy, stroke outcomes, diabetic neuropathy, Crohn’s disease, ulcerative colitis, schizophrenia, bipolar illness, and obsessive compulsive disorder; it can also be useful as a chelator for heavy metals and nanoparticles. There are also a number of other conditions that may show benefit; however, the evidence is not as robust. Conclusion. The use of N-acetylcysteine should be considered in a number of conditions as our population ages and levels of glutathione drop. Supplementation may contribute to reducing morbidity and mortality in some chronic conditions as outlined in the article.

show abstract

Effect of N-Acetylcysteine on Dyslipidemia and Carbohydrate Metabolism in STZ-Induced Diabetic Rats

Cited by 14 publications

References 57 publications

N-acetyl cysteine can blunt metabolic and cardiovascular effects via down-regulation of cardiotrophin-1 in rat model of fructose-induced metabolic syndrome

N-acetyl cysteine can blunt metabolic and cardiovascular effects via down-regulation of cardiotrophin-1 in rat model of fructose-induced metabolic syndrome

Zingerone (4-(4-hydroxy-3-methylphenyl) butan-2-one) protects against alloxan-induced diabetes via alleviation of oxidative stress and inflammation: Probable role of NF-kB activation

N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks)

Contact Info

Product

Resources

About